102308-53-2

Basic information

• Product Name: 1H-Indol-6-amine,2-methyl-(9CI)
• Synonyms: 1H-Indol-6-amine,2-methyl-(9CI);2-Methyl-1H-Indol-6-aMine;6-AMino-2-Methyl-1H-indole;1H-Indol-6-amine, 2-methyl-
• CAS NO: 102308-53-2
• Molecular Formula: C₉H₁₀N₂
• Molecular Weight: 146.192
• Product Categories: AMINEPRIMARY
• Mol File: 102308-53-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1H-Indol-6-amine,2-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indol-6-amine,2-methyl-(9CI)(102308-53-2)
• EPA Substance Registry System: 1H-Indol-6-amine,2-methyl-(9CI)(102308-53-2)

Safety Data

• Hazardous Substances Data: 102308-53-2(Hazardous Substances Data)

Usage

Uses

2-Methyl-1H-indol-6-amine is used in the synthesis of aza-podophyllotoxin derivatives, with some compounds exhibiting stronger growth inhibition activity in cancer cell lines (Zr-75-1, MCF7, KB, Gurav, DWD, Colo-205, A-549 and Hop62).

Upstream product

• 3484-23-9 2-methyl-6-nitro-1H-indole 
• 7647-01-0 hydrogenchloride 
• 945655-37-8 6-amino-2-methyl-1H-indole-3-carboxylic acid ethyl ester 
• 7664-93-9 sulfuric acid 
• 4993-93-5 4-nitro-1H-indole-2-carboxylic acid ethyl ester 
• 1056933-72-2 (E)-ethyl 2-(2-(3-nitrophenyl)hydrazono)propanoate 
• 134747-25-4 ethyl 2-[2-(3-nitrophenyl)hydrazinylidene]propanoate 
• 584-48-5 2,4-dinitrobromobenzene 
• 5465-68-9 2-(2,4-dinitrophenyl)-3-oxobutyric acid ethyl ester 
• 97-00-7 1-chloro-2,4-dinitro-benzene 

Downstream Products

• 132515-38-9 N-(2-methyl-indol-6-yl)-benzamide 
• 1186120-97-7 C₁₇H₁₄N₄O 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Process for dyeing keratinous fibres combining isatin or its derivatives with an aminoindole or an aminoindoline, and compositions used

The invention relates to a process for dyeing keratinous fibres, comprising the simultaneous or sequential application of a composition (A) containing a compound of formula (I): STR1 in which: R1 denotes hydrogen, alkyl, acetyl, benzoyl, phenyl or C1 -C4 carboxyalyl (sic); R2 and R3 denote hydrogen, alkyl, alkoxy, hydroxyalkyl, amino, halogen, nitro, alkylphenyl, phenyl, alkylamino, hydroxyalkylamino; and a composition (B) containing at least one compound of formula (II): STR2 in which: R4 and R6 denote hydrogen, alkyl; R5 denotes hydrogen, alkyl, COOR' where R' is hydrogen or alkyl; Z1 represents hydrogen, halogen, alkyl, alkoxy or hydroxyl; Z2 represents hydrogen or alkyl or a compound of formula (III): STR3 in which: R7 and R8 denote hydrogen or alkyl; X1 and X2 represent hydrogen or an NH2 radical; R9 denotes hydrogen, alkyl, alkoxy; as well as the compositions used.